Skip to main content
Hester Biosciences Ltd logo

Hester Biosciences Ltd — Investor Relations & Filings

Ticker · HESTERBIO ISIN · INE782E01017 LEI · 984500836B9EB1DC4935 BSE.NS Manufacturing
Open in API
Filings indexed 672 across all filing types
Latest filing 2022-11-16 Regulatory Filings
Country IN India
Listing BSE.NS HESTERBIO

About Hester Biosciences Ltd

https://www.hester.in/

Hester Biosciences Ltd specializes in the development, manufacturing, and marketing of animal healthcare products. The company primarily focuses on two segments: poultry healthcare and livestock healthcare. Its extensive product portfolio includes a wide range of live and inactivated vaccines, as well as health products such as therapeutics, herbal supplements, and disinfectants. Hester is recognized for its significant contributions to global animal disease control programs, particularly in the eradication of Peste des Petits Ruminants (PPR) and Brucellosis. The company operates advanced manufacturing facilities and maintains a robust distribution network to serve domestic and international markets. By leveraging research and development, Hester provides diagnostic services and technical support to enhance animal productivity and welfare. Its commitment to quality and innovation has established it as a key provider of biologicals and health solutions for the veterinary sector.

Recent filings

Filing Released Lang Actions
Related Party Transaction
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions for the half year ended 30 September 2022, submitted pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains detailed tabular data on transactions between the company and its related parties, including subsidiaries, joint ventures, promoters, directors, and key management personnel. The document is a regulatory disclosure filing required by stock exchanges and regulators, not a full financial report like an interim or annual report. It is not a certification or a brief announcement but a detailed disclosure of related party transactions. Such disclosures are typically classified under Regulatory Filings (RNS) as they do not constitute standalone financial reports but are regulatory compliance documents.
2022-11-16 English
Newspaper Advertisements
Regulatory Filings
2022-11-07 English
Transcript of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held on 4 November 2022 discussing the unaudited financial results for the quarter and half year ended 30 September 2022. It includes detailed management commentary on business divisions, financial performance, profitability, and future outlook. The presence of a moderator, management speakers, and Q&A format confirms it is a call transcript. The document is lengthy (15,000 characters) and contains substantive financial discussion, not just an announcement or summary. Therefore, it fits the category of a Call Transcript (CT).
2022-11-07 English
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short announcement informing about the availability of the audio recording of the earnings conference call for the quarter and half year ended 30 September 2022. It references the earnings call but does not contain the transcript or financial data itself. The document length is only 1081 characters, indicating it is a brief notice rather than a full report. According to the rules, announcements about availability of recordings or reports without the actual content should be classified as Regulatory Filings (RNS).
2022-11-04 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is dated 4 November 2022 and is addressed to stock exchanges (BSE and NSE) with reference to the outcome of a Board Meeting. It announces the approval of standalone and consolidated unaudited financial results for the quarter and half year ended 30 September 2022. The document includes detailed financial highlights, profitability analysis, business segment updates, and future outlook. It also contains a press release with comprehensive financial data and operational commentary. The presence of unaudited financial results for a quarter and half year period, along with detailed financial tables and analysis, indicates this is a quarterly/interim financial report. The document is over 11,000 characters, so it is not a mere announcement or publication notice. It contains substantive financial data and analysis, not just a summary or press release without financials. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2022-11-04 English
Outcome of Board Meeting
Regulatory Filings
2022-11-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.